Enliven Therapeutics ELVN Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's additional paid-in capital?
- Enliven Therapeutics (ELVN) reported additional paid-in capital of $824.48M in Q1 2026.
- How has Enliven Therapeutics's additional paid-in capital changed year-over-year?
- Enliven Therapeutics's additional paid-in capital increased by 47.2% year-over-year, from $560.28M to $824.48M.
- What is the long-term trend for Enliven Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Enliven Therapeutics's additional paid-in capital has grown at a 34.9% compound annual growth rate (CAGR), from $180.53M to $806.37M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.